RPL20A Antibody

What is RPL20A and why is it important in research studies?

RPL20A (Ribosomal Protein L20A) is a component of the 60S subunit of the ribosome. Like other ribosomal proteins, it plays a crucial role in protein synthesis. In research, RPL20A is significant because:

• It functions as part of the large ribosomal subunit in the complex responsible for cellular protein synthesis

• It belongs to a family of highly conserved proteins across species, making it valuable for comparative studies in evolutionary biology

• Changes in ribosomal protein expression, including RPL20A, have been implicated in various diseases and cellular stress responses

For experimental applications, researchers typically use antibodies against RPL20A to study ribosome biogenesis, stress responses, and related cellular processes. Understanding ribosomal proteins provides insights into fundamental cellular mechanisms of protein synthesis and their dysregulation in disease states.

What are the recommended validation methods for RPL20A antibody before experimental use?

A multi-tiered validation approach is recommended for RPL20A antibody to ensure specificity and reliability:

For comprehensive validation, implement at least 2-3 of these approaches. At minimum, verify the antibody produces the expected subcellular localization pattern and shows a band of the correct molecular weight in western blot when using positive control samples .

What applications are RPL20A antibodies typically used for in research?

Based on validated applications of similar ribosomal protein antibodies, RPL20A antibodies are suitable for multiple research applications:

Each application requires optimization for specific experimental conditions. When transitioning between applications, re-validation is recommended to ensure reliability .

How should I optimize Western blot conditions for RPL20A antibody?

Optimization of Western blot conditions for RPL20A antibody requires systematic adjustment of several parameters:

• Sample preparation:

  • Use appropriate lysis buffers containing protease inhibitors

  • For ribosomal proteins, RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) with fresh protease inhibitors is recommended

  • Load 20-30 μg of total protein per lane for whole cell lysates

• Gel selection:

  • RPL20A has a relatively low molecular weight (~18-20 kDa)

  • Use 15% SDS-PAGE gels for optimal resolution in this range

• Transfer conditions:

  • Transfer at 100V for 1 hour or 30V overnight at 4°C

  • Use PVDF membrane for better protein retention

• Blocking and antibody incubation:

  • Block with 5% non-fat dry milk in TBST (TBS with 0.1% Tween-20)

  • Start with 1:500 dilution for primary antibody incubation overnight at 4°C

  • Use 1:5000-1:10000 dilution for HRP-conjugated secondary antibody

• Detection:

  • ECL (enhanced chemiluminescence) systems work well for most applications

  • For low abundance, consider using more sensitive ECL substrates

Potential troubleshooting steps for common issues:

• Multiple bands: Increase antibody dilution or add additional wash steps

• No signal: Decrease antibody dilution or increase protein loading

• High background: Increase blocking time or add 0.1% BSA to antibody dilution buffer

What considerations are important when designing immunoprecipitation experiments with RPL20A antibody?

When designing immunoprecipitation (IP) experiments with RPL20A antibody, consider these critical factors:

• Lysis buffer composition:

  • For studying core ribosomal interactions: Use gentler lysis buffers (e.g., 25 mM HEPES pH 7.5, 150 mM NaCl, 0.5% NP-40, 1 mM EDTA with protease inhibitors)

  • For studying only tightly-bound interactions: Use more stringent buffers with higher salt concentrations

• Cross-linking considerations:

  • For transient interactions: Consider in vivo cross-linking with formaldehyde (1% for 10 minutes)

  • For stable interactions: Cross-linking may be unnecessary and could interfere with epitope recognition

• Antibody amount optimization:

  • Start with 2-4 μg antibody per 1 mg of total protein lysate

  • Scale up or down based on preliminary results

• Control experiments:

  • Include IgG control from the same species as the RPL20A antibody

  • Consider using lysate from RPL20A-depleted cells as negative control

• Elution strategies:

  • For downstream applications sensitive to pH changes: Use competitive elution with RPL20A peptide

  • For standard applications: Glycine elution (pH 2.5) followed by immediate neutralization

• Validation of IP success:

  • Confirm RPL20A presence in eluates via Western blot

  • Consider mass spectrometry to identify binding partners

For Co-IP experiments specifically designed to identify RPL20A binding partners, use buffer conditions that preserve physiologically relevant interactions while reducing non-specific binding .

How can I optimize immunohistochemistry (IHC) or immunofluorescence (IF) protocols for RPL20A antibody?

Optimization of IHC/IF protocols for RPL20A antibody requires attention to several key steps:

• Fixation methods:

  • 4% paraformaldehyde (PFA) for 10-15 minutes is usually suitable for cultured cells

  • For tissue sections, 4% PFA overnight followed by proper antigen retrieval is recommended

  • Avoid over-fixation which can mask epitopes

• Antigen retrieval methods:

  • Heat-induced epitope retrieval: Citrate buffer (pH 6.0) or Tris-EDTA buffer (pH 9.0)

  • Test both methods to determine optimal conditions

  • Typical protocol: 20 minutes at 95-100°C followed by 20 minutes cooling

• Permeabilization optimization:

  • For cells: 0.1-0.5% Triton X-100 in PBS for 5-10 minutes

  • For tissue sections: 1% Triton X-100 in PBS may be necessary

• Blocking protocol:

  • Use 5-10% normal serum from the same species as the secondary antibody

  • Add 0.1-0.3% Triton X-100 and 1% BSA to blocking buffer

  • Block for at least 1 hour at room temperature

• Antibody dilution and incubation:

  • Start with 1:100-1:200 dilution for primary antibody

  • Optimize incubation time (2 hours at room temperature or overnight at 4°C)

  • For secondary antibody, use 1:500-1:1000 dilution with 1-hour incubation

• Signal detection and enhancement:

  • For IF: Consider tyramide signal amplification if signal is weak

  • For IHC: Optimize DAB development time (typically 2-10 minutes)

For tissues with high autofluorescence, consider using Sudan Black B (0.1-0.3% in 70% ethanol) treatment after secondary antibody incubation but before mounting to reduce background .

How do I interpret unexpected Western blot results when using RPL20A antibody?

When interpreting unexpected Western blot results with RPL20A antibody, consider these common scenarios and their potential causes:

• Multiple bands observed:

  • Expected RPL20A band (~18-20 kDa) plus additional bands:

    • Post-translational modifications (phosphorylation, ubiquitination)

    • Degradation products (add fresh protease inhibitors)

    • Cross-reactivity with other ribosomal proteins (validate with specific controls)

    • Alternative splice variants (verify with RNA analysis)

• Band at unexpected molecular weight:

  • Band significantly larger than expected (>25 kDa):

    • Post-translational modifications

    • Dimerization or complex formation (use reducing conditions)

    • Antibody cross-reactivity (validate with knockout controls)

  • Band significantly smaller than expected (<15 kDa):

    • Degradation (improve sample preparation)

    • Antibody recognizing truncated isoforms

• No detectable signal:

  • Epitope masking: Try different lysis buffers or denaturing conditions

  • Low expression: Increase protein load or use enrichment methods

  • Batch variation: Test antibody with known positive control

• Inconsistent results between experiments:

  • Antibody storage issues: Avoid freeze-thaw cycles

  • Sample degradation: Use fresh samples or improve storage

  • Technical variation: Standardize protocols and use loading controls

For validation, consider comparative analysis with multiple antibodies targeting different epitopes of RPL20A, as independent epitope validation is one of the strongest approaches to confirm antibody specificity .

How can I differentiate between specific and non-specific staining in immunohistochemistry with RPL20A antibody?

Differentiating between specific and non-specific staining requires systematic analysis:

• Expected localization pattern:

  • RPL20A should primarily show cytoplasmic and nucleolar localization

  • Strong nucleolar staining is characteristic of ribosomal proteins

  • Cytoplasmic staining represents mature ribosomes

• Control samples for validation:

  • Positive control: Tissue or cells known to express RPL20A

  • Negative control: Sample without primary antibody

  • Specificity control: RPL20A-depleted cells or competitive peptide blocking

• Assessment criteria for specific staining:

  • Consistent with known biology of RPL20A

  • Reproducible across technical replicates

  • Absent in negative controls

  • Reduces/disappears with competitive peptide blocking

  • Correlates with other detection methods for RPL20A

• Characteristics of non-specific staining:

  • Often diffuse rather than compartmentalized

  • Present in negative controls

  • Shows irregular or inconsistent pattern between samples

  • Not affected by competitive blocking

  • Often appears at tissue edges or in necrotic areas

• Quantitative assessment:

  • Compare signal-to-background ratios across samples

  • Use digital image analysis to measure staining intensity in expected compartments

For definitive validation, apply the independent epitope approach by comparing staining patterns using two different antibodies targeting non-overlapping epitopes of RPL20A - this is considered one of the strongest validation methods as the probability of two antibodies showing identical non-specific staining is extremely low .

What are the common reasons for high background in immunofluorescence experiments with RPL20A antibody?

High background in immunofluorescence with RPL20A antibody can result from multiple sources:

For tissue sections with particularly high background, consider implementing additional washing steps with higher salt PBS (300-500 mM NaCl) to reduce non-specific ionic interactions. For cells expressing endogenous IgG (like B cells), use isotype-specific secondary antibodies and include an Fc receptor blocking step .

How can I use RPL20A antibody to study ribosome biogenesis defects in disease models?

RPL20A antibody can be a powerful tool for investigating ribosome biogenesis defects in disease models through several advanced approaches:

• Nucleolar stress monitoring:

  • RPL20A relocalization from nucleolus to nucleoplasm is an indicator of nucleolar stress

  • Use co-immunofluorescence with RPL20A antibody and established nucleolar markers like fibrillarin

  • Quantify changes in nucleolar-to-nucleoplasmic signal ratio in response to disease-relevant stimuli

• Ribosomal subunit assembly analysis:

  • Use RPL20A antibody in conjunction with gradient fractionation to monitor 60S subunit assembly

  • Protocol outline:

    • Lyse cells in polysome buffer (10 mM HEPES pH 7.4, 100 mM KCl, 5 mM MgCl2, 1 mM DTT, 100 μg/ml cycloheximide)

    • Fractionate lysate on 10-50% sucrose gradient

    • Collect fractions and analyze by Western blot with RPL20A antibody

    • Changes in RPL20A distribution across fractions indicate assembly defects

• Translational stress response monitoring:

  • RPL20A localization and expression levels change during cellular stress

  • Compare disease models vs. controls using quantitative immunofluorescence

  • Correlate with other stress markers like phospho-eIF2α

• Ribosome heterogeneity assessment:

  • Use RPL20A antibody in translating ribosome affinity purification (TRAP)

  • Protocol steps:

    • Express tagged RPL20A in specific cell populations

    • Immunoprecipitate intact ribosomes using RPL20A antibody

    • Analyze associated mRNAs by RNA-seq

    • Compare ribosome-associated transcriptomes between disease and control states

• Ribosomal protein imbalance in disease:

  • Quantify relative RPL20A levels compared to other ribosomal proteins

  • Use RPL20A antibody alongside antibodies for other ribosomal proteins (RPL22, RPL10A)

  • Analyze by quantitative Western blot or mass spectrometry

This multi-faceted approach provides comprehensive insights into how ribosome dysfunction contributes to disease pathogenesis across multiple models including cancer, neurodegenerative disorders, and ribosomopathies .

What approaches can be used to validate anti-RPL20A antibody specificity in the context of ribosomal protein cross-reactivity?

Ribosomal proteins share significant homology, making cross-reactivity a particular concern for RPL20A antibodies. Use these advanced validation approaches to ensure specificity:

• CRISPR/Cas9-mediated gene editing:

  • Generate RPL20A knockout or knockdown cells

  • Compare antibody signal between wildtype and RPL20A-depleted cells via Western blot and immunofluorescence

  • Quantify signal reduction (>90% reduction expected for specific antibodies)

• Mass spectrometry validation:

  • Perform immunoprecipitation with RPL20A antibody

  • Analyze precipitated proteins by LC-MS/MS

  • A specific antibody should predominantly enrich RPL20A peptides

  • Quantitative assessment: RPL20A peptides should be among top 3 most abundant proteins in IP sample

• Competitive epitope blocking:

  • Pre-incubate RPL20A antibody with:

    • Purified recombinant RPL20A protein

    • Purified recombinant proteins of close homologs (RPL20B, RPL22, etc.)

  • Specific antibody signal should be blocked only by RPL20A protein, not by homologs

• Binding kinetics analysis:

  • Use surface plasmon resonance (SPR) to measure:

    • Binding affinity (KD) to RPL20A

    • Cross-reactivity with other ribosomal proteins

  • Compare affinity constants to determine specificity ratio

  • High-specificity antibodies show >100-fold higher affinity for target vs. homologs

• Epitope mapping:

  • Identify specific epitope using peptide arrays or hydrogen-deuterium exchange mass spectrometry

  • Compare epitope sequence with other ribosomal proteins to identify unique regions

  • Select antibodies targeting regions with minimal homology to other ribosomal proteins

• Orthogonal detection methods:

  • Correlate antibody results with mRNA levels (RT-qPCR)

  • Use RPL20A-GFP fusion proteins to validate antibody co-localization

For highest confidence validation, implement at least three independent approaches, including at least one genetic approach and one biochemical approach .

How can RPL20A antibody be used in investigating translational control during cellular stress?

RPL20A antibody enables sophisticated analysis of translational control during stress through these advanced methodologies:

• Stress granule association studies:

  • Stress conditions (arsenite, heat shock) induce stress granule formation

  • Protocol for co-localization analysis:

    • Treat cells with stress inducers (e.g., sodium arsenite at 0.5-1 mM for 30-60 minutes)

    • Fix cells and perform co-immunofluorescence with:

      • RPL20A antibody

      • Stress granule markers (G3BP1, TIA-1)

    • Quantify co-localization coefficient to determine ribosomal protein recruitment to stress granules

• Polysome profiling during stress:

  • Examine translation complex assembly under stress

  • Detailed methodology:

    • Treat cells with stress inducers

    • Prepare cytoplasmic extracts in polysome buffer with cycloheximide

    • Fractionate on 10-50% sucrose gradients

    • Collect fractions and analyze RPL20A distribution by Western blot

    • Compare polysome/monosome ratios between stressed and unstressed conditions

• Stress-induced ribosomal protein post-translational modifications:

  • Stress conditions trigger modifications affecting translation

  • Investigation approach:

    • Immunoprecipitate RPL20A under normal and stress conditions

    • Analyze by mass spectrometry to identify stress-induced PTMs

    • Perform Western blot with phospho-specific or ubiquitin-specific antibodies

    • Correlate modifications with functional readouts of translation

• Selective mRNA translation analysis:

  • Combine RPL20A antibody with RNA-seq to identify stress-regulated transcripts

  • Translating Ribosome Affinity Purification (TRAP) workflow:

    • Express epitope-tagged RPL20A in cells of interest

    • Subject cells to stress conditions

    • Immunoprecipitate ribosomes using anti-epitope antibody

    • Extract and sequence associated mRNAs

    • Compare transcripts associated with ribosomes under normal vs. stress conditions

• Real-time visualization of translation dynamics:

  • Combine RPL20A antibody with puromycylation to visualize active translation sites

  • Protocol:

    • Treat cells with puromycin briefly (5-10 minutes at 10 μg/ml)

    • Fix and perform co-immunofluorescence for:

      • RPL20A (ribosomes)

      • Anti-puromycin antibody (nascent peptides)

    • Analyze co-localization before and during stress response

These approaches provide multilayered insights into how ribosome composition and activity are dynamically regulated during cellular stress responses, with applications in understanding disease mechanisms where stress response pathways are dysregulated .

What considerations are important when designing experiments to study RPL20A interactions with RNA-binding proteins or regulatory RNAs?

Studying RPL20A interactions with RNA-binding proteins (RBPs) or regulatory RNAs requires specialized experimental approaches:

• Optimized immunoprecipitation conditions:

  • RNA-protein complexes require careful buffer optimization:

    • Use low-salt buffers (100-150 mM NaCl) to preserve interactions

    • Include RNase inhibitors (40 U/ml RNasin or SUPERase- In)

    • Consider mild detergents (0.1-0.5% NP-40 or Triton X-100)

    • Add EDTA (1-5 mM) to inhibit ribonucleases

  • For RNA-dependent interactions:

    • Perform parallel IPs with and without RNase treatment

    • Interactions that disappear after RNase treatment are RNA-dependent

• Cross-linking methodologies:

  • For protein-RNA interactions:

    • UV cross-linking (254 nm for 30-60 seconds)

    • Formaldehyde cross-linking (0.1-1% for 10 minutes)

    • Specialized cross-linkers like DSS for protein-protein interactions

  • For capturing transient interactions:

    • PAR-CLIP (Photoactivatable-Ribonucleoside-Enhanced Crosslinking)

    • CLIP-seq (Cross-Linking Immunoprecipitation followed by sequencing)

• Electrophoretic Mobility Shift Assay (EMSA):

  • To test direct RNA binding:

    • Express and purify recombinant RPL20A

    • Prepare radiolabeled or fluorescently labeled RNA probes

    • Mix protein and RNA in binding buffer (25 mM HEPES pH 7.6, 50 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.1 mg/ml BSA)

    • Resolve complexes on 5% native polyacrylamide gel

    • Include competition assays with unlabeled RNA

• RNA immunoprecipitation (RIP) protocol optimization:

  • Cell lysis in appropriate buffer (e.g., 25 mM Tris-HCl pH 7.5, 150 mM KCl, 0.5% NP-40, 1 mM EDTA, RNase inhibitors)

  • Pre-clear lysate with protein A/G beads

  • Incubate with RPL20A antibody (4-10 μg per sample) overnight at 4°C

  • Extract RNA from immunoprecipitates using TRIzol or commercial kits

  • Analyze by RT-qPCR or RNA-seq

• Proximity-based interaction studies:

  • BioID or TurboID fusion with RPL20A to identify proximal proteins

  • APEX2 fusion for temporal control of labeling

  • RNA-protein proximity labeling using APEX-seq for RNA interactome

• Validation of functional relevance:

  • Mutate predicted RNA binding residues in RPL20A

  • Perform rescue experiments in RPL20A-depleted cells

  • Correlate binding with functional readouts (translation efficiency, ribosome biogenesis)

When reporting results, quantitative assessment of binding parameters (Kd values, stoichiometry) provides more mechanistic insights than simple qualitative binding data .

What are the most effective strategies to troubleshoot antibody batch variation when using RPL20A antibody?

Antibody batch variation is a significant challenge in research reproducibility. For RPL20A antibody, implement these systematic approaches:

• Comprehensive batch validation protocol:

  • Upon receiving new batch:

    • Perform side-by-side Western blot comparison with previous batch

    • Test serial dilutions (1:100, 1:500, 1:1000, 1:5000) to determine optimal concentration

    • Compare signal-to-noise ratio at each dilution

    • Document and archive validation results for laboratory records

• Reference standard development:

  • Create laboratory reference standard:

    • Prepare large batch of positive control lysate (e.g., HeLa cells)

    • Aliquot and store at -80°C

    • Use identical aliquot with each new antibody batch

    • Quantify relative signal intensity normalized to loading control

• Epitope-specific validation:

  • For polyclonal antibodies:

    • Different batches may recognize different epitopes

    • Perform epitope mapping or peptide blocking

    • Consider affinity purification against the immunizing peptide

  • For monoclonal antibodies:

    • Verify clone identity between batches

    • Request hybridoma testing data from manufacturer

• Data normalization strategies:

  • Internal standardization:

    • Include standard curve on each blot

    • Use digital image analysis for quantitative comparisons

    • Calculate correction factors between batches

• Long-term antibody storage optimization:

  • Minimize freeze-thaw cycles:

    • Aliquot antibody upon receipt

    • Store at -20°C (or -80°C for long-term)

    • Add carrier protein (BSA) if not present

    • Monitor for signs of degradation (precipitation, color change)

• Alternative detection strategies:

  • If batch variation persists:

    • Consider direct labeling (fluorophore or enzyme conjugation)

    • Use recombinant antibodies when available

    • Implement complementary detection methods (e.g., mass spectrometry)

Establishing a detailed antibody validation database within your laboratory with images, dilutions, and experimental conditions for each batch creates institutional knowledge that improves research continuity and reproducibility .

How can researchers optimize RPL20A antibody use across different tissue types and fixation methods?

Different tissue types and fixation methods significantly impact RPL20A antibody performance. Use these optimization strategies:

• Systematic fixation comparison:

  • Test multiple fixation protocols in parallel:

    • 4% PFA (10 minutes, 30 minutes, overnight)

    • Methanol (-20°C, 10 minutes)

    • Acetone (-20°C, 10 minutes)

    • Combined PFA/methanol (PFA followed by methanol)

  • Evaluate signal intensity, background, and specificity for each method

• Tissue-specific antigen retrieval optimization:

  • Develop a retrieval method matrix:

  Tissue Type	Recommended Primary Retrieval	Alternative Method	Special Considerations
  Brain	Citrate buffer (pH 6.0), 95°C, 20 min	EDTA buffer (pH 9.0)	High lipid content may require extended retrieval
  Liver	EDTA buffer (pH 9.0), 95°C, 20 min	Enzymatic (proteinase K)	High background risk; extend blocking
  Lung	Citrate buffer (pH 6.0), 95°C, 15 min	Tris-EDTA (pH 9.0)	Endogenous peroxidase blocking critical
  Heart	Tris-EDTA (pH 9.0), 95°C, 30 min	High-pressure cooking	Dense tissue may require extended retrieval
  Kidney	EDTA buffer (pH 8.0), 95°C, 20 min	Citrate buffer (pH 6.0)	Endogenous biotin blocking may be necessary

  • Validate optimal method for each tissue type

• Permeabilization optimization:

  • For cell membranes: 0.1-0.3% Triton X-100 (5-15 minutes)

  • For tissue sections: 0.5-1.0% Triton X-100 (15-30 minutes)

  • For challenging tissues: Consider SDS permeabilization (0.1-0.5% for 5 minutes)

• Detergent screening for antibody dilution buffer:

  • Test different detergents in antibody dilution buffer:

    • Triton X-100 (0.1-0.3%)

    • Tween-20 (0.05-0.1%)

    • Saponin (0.1-0.5%)

  • Evaluate which provides optimal signal-to-noise ratio

• Tissue-specific blocking strategies:

  • For tissues with high endogenous biotin: Add avidin/biotin blocking step

  • For tissues with high background: Use serum from secondary antibody species plus 1% BSA

  • For high autofluorescence: Include Sudan Black B treatment (0.1-0.3% in 70% ethanol)

• Signal amplification for low-expression tissues:

  • Tyramide signal amplification

  • Polymer-based detection systems

  • Quantum dot conjugates for fluorescence

• Tissue-specific positive and negative controls:

  • Identify tissue-specific positive controls with known RPL20A expression

  • Use genetically modified tissues (conditional knockouts if available) as negative controls

Document all optimization parameters in a tissue-specific protocol database to ensure reproducibility across experiments and between laboratory members .

What controls and validation are necessary when using RPL20A antibody in co-immunoprecipitation studies to identify novel interaction partners?

Co-immunoprecipitation (Co-IP) with RPL20A antibody to identify novel interaction partners requires rigorous controls and validation:

• Essential experimental controls:

  • Input control: 5-10% of lysate used for IP

  • Negative controls:

    • IgG from same species as RPL20A antibody

    • Lysate from RPL20A-depleted cells

    • Beads-only control

  • Specificity controls:

    • Competitive peptide blocking

    • Reciprocal IP with antibodies against putative interactors

• Stringency optimization strategy:

  • Perform parallel IPs with increasing salt concentration:

    • Low stringency: 100 mM NaCl

    • Medium stringency: 150-250 mM NaCl

    • High stringency: 300-500 mM NaCl

  • Compare interactome profiles to distinguish specific from non-specific interactions

  • True interactors should persist at higher stringency while contaminants decrease

• Cross-linking validation approach:

  • Perform parallel IPs with and without cross-linking

  • Recommended cross-linkers:

    • DSP (dithiobis(succinimidyl propionate)), membrane permeable

    • Formaldehyde (1% for 10 minutes)

  • Interactions detected both with and without cross-linking represent high-confidence partners

• RNase/DNase treatment controls:

  • Perform parallel IPs with and without nuclease treatment:

    • RNase A/T1 mix (100 μg/ml, 30 minutes at 37°C)

    • DNase I (100 U/ml, 30 minutes at 37°C)

  • Interactions lost after nuclease treatment are nucleic acid-dependent

  • Document which interactions are direct protein-protein vs. nucleic acid-mediated

• Quantitative validation methodology:

  • SILAC or TMT labeling for quantitative proteomics

  • Compare abundance ratios (RPL20A-IP/IgG-IP)

  • Establish statistical threshold for specific interactions (typically >2-fold enrichment with p<0.05)

  • Create rank-ordered list of interactions based on enrichment factor

• Biological validation of novel interactions:

  • Orthogonal confirmation methods:

    • Proximity ligation assay (PLA)

    • Fluorescence resonance energy transfer (FRET)

    • Bimolecular fluorescence complementation (BiFC)

  • Functional validation:

    • siRNA knockdown of interaction partner

    • Effect on RPL20A localization or function

    • Mutational analysis of interaction interfaces

• Bioinformatic analysis of interaction networks:

  • Compare with known ribosomal protein interactomes

  • Analyze for enriched functional categories (GO terms)

  • Predict structural basis for interactions

These comprehensive controls and validation approaches ensure that reported novel interaction partners represent physiologically relevant associations rather than experimental artifacts .